GleamWall
中文EN

CATX Perspective Therapeutics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 728387 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.2%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.8%
ROA-37.2%
ROIC (approx.)-44.1%
Asset turnover—

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.01x
Current ratio5.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$26.07M$21.54M$21.37M$32.92M$20.34M$16.62M$14.33M$12.88M
SG&A expense$8.27M$7.79M$6.99M$6.95M$7.73M$7.71M$7.84M$8.25M
Operating income-$34.32M-$29.26M-$28.28M-$39.83M-$27.86M-$24.04M-$21.83M-$44.98M
Pretax income-$32.44M-$26.98M—-$38.28M-$25.97M-$22.00M-$18.18M-$42.27M
Net income-$32.44M-$26.79M-$26.19M-$37.49M-$25.97M-$21.48M-$18.18M-$40.17M
EBITDA-$33.13M-$28.12M-$27.16M-$38.82M-$27.09M-$23.31M-$21.10M-$44.26M
EPS (basic)-0.27-0.22-0.25—-0.35-0.29-0.25—
EPS (diluted)-0.27-0.22-0.25—-0.35-0.29-0.25—
Weighted avg. shares (diluted)120.75M120.65M103.60M—74.30M74.23M72.36M—
Balance sheet
Cash & equivalents$41.04M$48.49M$53.97M$30.63M$26.76M$28.85M$44.41M$61.58M
Short-term investments$160.65M$188.39M$216.96M$114.11M$147.38M$162.73M$167.30M$165.34M
Receivables$13,000$269,000$58,000$6,000$179,000$225,000$78,000$116,000
Current assets$205.28M$241.52M$275.35M$148.39M$178.50M$195.96M$215.74M$231.16M
PP&E, net$117.92M$107.80M$92.48M$76.60M$64.35M$62.60M$61.25M$57.32M
Goodwill———————$0
Intangibles———$362,000———$279,000
Total assets$365.68M$392.02M$410.77M$266.97M$294.82M$310.73M$329.35M$341.10M
Current liabilities$39.60M$36.54M$31.49M$28.68M$20.62M$12.99M$12.68M$18.23M
Long-term debt$1.58M$1.60M$1.61M$1.62M$1.64M$1.65M$1.66M$1.68M
Total debt$1.58M$1.60M$1.61M$1.62M$1.64M$1.65M$1.66M$1.68M
Total liabilities$71.00M$68.16M$63.33M$59.94M$52.61M$45.03M$44.70M$50.43M
Shareholders' equity$294.68M$323.86M$347.44M$207.03M$242.22M$265.69M$284.64M$290.67M
Net debt-$39.46M-$46.89M-$52.36M-$29.00M-$25.12M-$27.20M-$42.74M-$59.90M
Shares outstanding114.16M114.09M114.02M74.34M74.34M74.26M74.05M70.67M
Cash flow statement
Operating cash flow-$31.35M-$20.65M-$31.47M-$24.66M-$16.29M-$19.95M-$21.58M-$26.61M
Capital expenditure$4.54M$14.20M$6.86M$5.08M$1.99M$1.03M$4.66M$14.61M
Free cash flow-$35.89M-$34.84M-$38.33M-$29.73M-$18.28M-$20.98M-$26.24M-$41.22M
Investing cash flow$23.73M$15.02M-$109.55M$28.54M$13.99M$4.26M-$5.57M-$138.60M
Financing cash flow$175,000$147,000$164.36M-$13,000$213,000$132,000$9.97M$345,000
Depreciation & amortization$1.19M$1.14M$1.13M$1.01M$775,000$733,000$732,000$721,000
Stock-based compensation$3.13M$3.05M$2.55M$2.31M$2.16M$2.40M$2.10M$2.06M

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.